Stephen Salloway

Advisor at Bolden Therapeutics

Dr. Salloway received his MD from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University. He is the Martin M. Zucker Professor of Psychiatry and Human Behavior, and Professor of Neurology at the Warren Alpert Medical School of Brown University, and Chief of Neurology and Director of the Memory and Aging Program at Butler Hospital. Dr. Salloway is an internationally recognized leader in clinical trials for the prevention and treatment of Alzheimer’s disease (AD). His program has conducted more than 100 clinical trials for AD and related disorders. He has chaired the Steering Committees for major AD pivotal trials and he has been a lead author for key publications in AD research in the New England Journal of Medicine, Nature and other top-tiered journals. He is the Past President of the American Neuropsychiatric Association, a Fellow of the American Academy of Neurology and a member of the American Neurological Association. He serves as a consultant for drug development to the NIH, the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation and many other groups working on AD therapeutics. He has published more than 400 scientific articles and abstracts and edited 3 books and he lectures widely about the early diagnosis and prevention of AD.

Timeline

  • Advisor

    Current role